biotech · Advanced Solid Tumor · Solid Tumor, Adult · IMMX
Immix Biopharma
Immix Biopharma is a biotech organization headquartered in Los Angeles, USA. It trades on NYSE under ticker IMMX. Primary therapeutic focus areas include Advanced Solid Tumor, Solid Tumor, Adult, Light Chain (AL) Amyloid
Los Angeles, USA HQ
2012 Founded
39 Employees
Public company Type
IMMX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Los Angeles, USA
- Founded
- 2012
- Employees
- 39
- Programs
- 3
- Drugs
- 2
- Patents
- 2
NXC-201 CAR-T
Phase 2 · mab · Light Chain (AL) Amyloidosis
NXC-201 CAR-T for Light Chain (AL) Amyloidosis is a Phase 2 program (mab) at Immix Biopharma with 1 ClinicalTrials.gov record(s).
Internal code NXC-201-AL-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Immix Biopharma
- Phase
- Phase 2
- Modality
- mab
- Indication
- Light Chain (AL) Amyloidosis
- Status
- active
- Trials
- 1